English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background and Aims . Fibronectin containing the extra domain A (ED-A +  Fn) was proven to serve as a valuable biomarker for cardiac remodeling. The study was aimed at establishing an ELISA to determine ED-A +  Fn in serum of heart failure patients.  Methods . ED-A +  Fn was quantified in serum samples from 114 heart failure patients due to ischemic (ICM,  n  = 44) and dilated (DCM,  n  = 39) cardiomyopathy as well as hypertensive heart disease (HHD,  n  = 31) compared to healthy controls ( n  = 12).  Results . In comparison to healthy volunteers, heart failure patients showed significantly increased levels of ED-A +  Fn ( p  < 0.001). In particular in ICM patients there were significant associations between ED-A +  Fn serum levels and clinical parameters, for example, increased levels with rising NYHA class ( p  = 0.013), a negative correlation with left ventricular ejection fraction ( p  = 0.026,  r : −0.353), a positive correlation with left atrial diameter ( p  = 0.008,  r : 0.431), and a strong positive correlation with systolic pulmonary artery pressure ( p  = 0.002,  r : 0.485). In multivariate analysis, ED-A +  Fn was identified as an independent predictor of an ischemic heart failure etiology.  Conclusions . The current study could clearly show that ED-A +  Fn is a promising biomarker in cardiovascular diseases, especially in heart failure patients due to an ICM. We presented a valid ELISA method, which could be applied for further studies investigating the value of ED-A +  Fn.

Detection of Soluble ED-A+Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling

Detection of Soluble ED-A⁺Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling